Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Trial Identifier: PT010001-00
Sponsor: Pearl Therapeutics, Inc.
NCTID:: NCT01980615
Start Date: November 2013
Primary Completion Date: December 2013
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, MD Baltimore, MD, United States